Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Phase 2

• Conditions: EGFR Positive Non-small Cell Lung Cancer
• Interventions: Drug: EGFR

• Registration Number: NCT03382795
• Lead Sponsor: Korea University Guro Hospital

Brief Summary

In this trial, treatment efficacy and safety of retreatment with 1st generation epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI)s(Gefitinib/Erlotinib), will be assessed in patients with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients who previously treated with EGFR TKI and cytotoxic chemotherapy

Detailed Description

This study is designed to be multi-center, open-label, single-arm, prospective, phase II trial of patient with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients who previously treated with EGFR TKI and cytotoxic chemotherapy. Approximately 69 patients will be enrolled into the trial, and expected study duration is 48 months from Institutional Review Board(IRB) and Korea Ministry of Food and Drug Safety(MFDS) approval date.

The study drug will be administered orally as one tablet(Gefitinib 250mg/ Erlotinib 150mg) once a day until disease progression or manifestation of unacceptable toxicity. The initial dose of the study drug daily can be reduced according to dose reduction criteria in protocol. A cycle of study treatment is defined as 28 days, and subjects will visit the site every 2 cycles(56 days).

Study Timeline

• Study First Submitted: 2017-12-19
• Study First Submitted QC: 2017-12-19
• Study First Posted: 2017-12-26
• Study Start: 2018-01-03
• Status Verified: 2021-07
• Last Update Submitted: 2021-07-13
• Last Update Posted: 2021-07-15
• Primary Completion: 2023-03-31
• Study Completion: 2023-03-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 63

Inclusion Criteria

1. Males or females ≥ 19 years of age

2. Non Small Cell Lung Cancer(Non-Squamous Cell Carcinoma) patients who had shown clinical benefits (Complete response(CR) or Partial response(PR) or Stable disease(SD) ≥6 months) from EGFR-TKIs as first line treatment and developed progressive disease, and then received cytotoxic chemotherapy more than 4 cycles and developed progressive disease, and then confirmed T790 negative and sensitizing EGFR mutation(E19Del, L858R, L861Q, G719X, E19insertion) positive in Histologic, cytologic specimen or blood.

3. Patient with at least one measurable lesions according to RECIST v 1.1

4. Expected life expectancy ≥ 12 weeks

5. Eastern Cooperative Oncology Group(ECOG) performance status ≤ 2

6. Patients who have proper hematologic, renal and hepatic functions as follows:

   • Absolute neutrophil count(ANC) ≥ 1,500/mm³
   • platelets ≥ 100,000/mm³
   • Hemoglobin ≥ 9g/dL
   • Total bilirubin ≤ 1.25 X UNL
   • Aspartate aminotransferase(AST or SGOT) and alanine aminotransferase(ALT or SGPT) ≤ 3.0 X UNL (if liver metastasis ≤5.0 X UNL)
   • Alkaline phosphatase ≤ 2.5 X UNL (if liver metastasis ≤5.0 X UNL)
   • Serum creatinine ≤ 1.5mg/dL

7. patients who are willing to comply with study procedure and voluntarily provide informed consent with signature

Read More

Exclusion Criteria

1. Patients who have preexisting or coexisting malignancies in other parts except for effectively treated non-melanoma skin cancer, cervical carcinoma in situ(CIS) cervical cancer within the last 5 years

2. Patients with brain metastasis except for the followings:

   • Asymptomatic and stable brain metastases for which local treatment has been given: corticosteroids treatment isn't requiured for at least 2 weeks before starting the study treatment.

3. Patients currently receiving palliative radiation therapy or have toxicities from radiation therapy at screening.

4. Patients with clinically active history of interstitial lung disease(ILD), Drug induced ILD, Radiation pneumonitis

5. Patients with clinically significant cardiovascular disease or myocardial infarction within the past 12 months.

6. Patients with active infection or severe systemic disease that are difficult to include in this study

7. Patients who received radiation therapy to target lesion of this study.

8. Patients who had major operation within 4 weeks before starting the study treatment and were not fully recovered.

9. Patients who were administered other study drugs within 4 weeks before starting the study treatment

10. Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive pregnancy test prior to study entry

11. Patients who are difficult to include in this study in accordance with the investigator's judgment

12. Patients with histories of hypersensitivity to investigational product(IP) or any components of the agent

13. Patients with any of the following genetic predispositions including galactose intolerance, Lapp lactase deficiency, lactose intolerance or glucose-galactose malabsorption

14. Patient previously received cytotoxic chemotherapy within 2 weeks of IP administration

15. Patient received Immunotherapy prior to the study participation

16. Patients who are difficult to include in this study in accordance with the investigator's judgment due to severe adverse effects during previous EGFR TKI treatment

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
EGFR retreat group	EGFR	-

Primary Outcome Measures

Name	Time	Method
Objective Response Rate(ORR) including rage of CR&PR	Through study completion (5 years)	Assessed on based of RECIST 1.1.

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival, PFS	Through study completion (5 years)	Progression-free survival (PFS) the time from first dose of the study drug until the date of disease progression or death by any cause
Overall Survival	Through study completion (5 years)	Overall Survival (OR) the time from first dose of the study drug until the date of death by any cause
The incidence of Adverse Events(including Serious Adverse Events and Adverse Drug Reactions)	Through study completion (5 years)	Assessment on the base of NCI-CTCAE (version 4.03)

Trial Locations

Locations (8)

Yonsei University Severance Hospital; 🇰🇷 Seoul, Korea, Republic of

Korea University Guro Hospital; 🇰🇷 Seoul, Korea, Republic of

Chungnam National University Hospital; 🇰🇷 Daejeon, Korea, Republic of

Chonnam National University Hwasun Hospital; 🇰🇷 Hwasun, Jeollanam-do, Korea, Republic of

Konkuk University Medical Center; 🇰🇷 Seoul, Korea, Republic of

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of

Hallym University Sacred Heart Hospital; 🇰🇷 Anyang, Gyeonggi-do, Korea, Republic of

Pusan National University Yangsan Hospital; 🇰🇷 Yangsan, Gyeongsangnam-do, Korea, Republic of